SG10201806715TA - Use of inos inhibitors to increase viral yield in culture - Google Patents

Use of inos inhibitors to increase viral yield in culture

Info

Publication number
SG10201806715TA
SG10201806715TA SG10201806715TA SG10201806715TA SG10201806715TA SG 10201806715T A SG10201806715T A SG 10201806715TA SG 10201806715T A SG10201806715T A SG 10201806715TA SG 10201806715T A SG10201806715T A SG 10201806715TA SG 10201806715T A SG10201806715T A SG 10201806715TA
Authority
SG
Singapore
Prior art keywords
culture
inos inhibitors
viral yield
increase viral
increase
Prior art date
Application number
SG10201806715TA
Other languages
English (en)
Inventor
Peter Pechan
Jeffery Ardinger
Abraham Scaria
Samuel Wadsworth
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of SG10201806715TA publication Critical patent/SG10201806715TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/245Herpetoviridae, e.g. herpes simplex virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651Methods of production or purification of viral material
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG10201806715TA 2013-01-08 2014-01-07 Use of inos inhibitors to increase viral yield in culture SG10201806715TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361750175P 2013-01-08 2013-01-08

Publications (1)

Publication Number Publication Date
SG10201806715TA true SG10201806715TA (en) 2018-09-27

Family

ID=51167323

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201806715TA SG10201806715TA (en) 2013-01-08 2014-01-07 Use of inos inhibitors to increase viral yield in culture
SG11201505333PA SG11201505333PA (en) 2013-01-08 2014-01-07 Use of inos inhibitors to increase viral yield in culture
SG10201913130PA SG10201913130PA (en) 2013-01-08 2014-01-07 Use of inos inhibitors to increase viral yield in culture

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG11201505333PA SG11201505333PA (en) 2013-01-08 2014-01-07 Use of inos inhibitors to increase viral yield in culture
SG10201913130PA SG10201913130PA (en) 2013-01-08 2014-01-07 Use of inos inhibitors to increase viral yield in culture

Country Status (20)

Country Link
US (2) US11299715B2 (ja)
EP (3) EP3521420A1 (ja)
JP (2) JP6534933B2 (ja)
KR (1) KR102307279B1 (ja)
CN (1) CN105008523B (ja)
AR (1) AR094389A1 (ja)
AU (1) AU2014205604B2 (ja)
BR (2) BR122020002822B1 (ja)
CA (1) CA2897444A1 (ja)
DK (1) DK2943567T3 (ja)
ES (1) ES2651763T3 (ja)
HK (2) HK1214840A1 (ja)
HU (1) HUE037482T2 (ja)
IL (1) IL239824B (ja)
MX (1) MX360470B (ja)
NO (1) NO3050055T3 (ja)
RU (1) RU2676733C2 (ja)
SG (3) SG10201806715TA (ja)
TW (1) TWI608102B (ja)
WO (1) WO2014110053A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201703148TA (en) 2014-11-05 2017-05-30 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
AU2015346162B2 (en) 2014-11-14 2022-02-10 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
ES2878451T3 (es) 2014-11-14 2021-11-18 Voyager Therapeutics Inc Polinucleótidos moduladores
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
PL3436593T3 (pl) 2016-03-28 2023-03-27 Ultragenyx Pharmaceutical Inc. Sposoby inaktywacji termicznej adenowirusów
AU2017267665C1 (en) 2016-05-18 2023-10-05 Voyager Therapeutics, Inc. Modulatory polynucleotides
EP3526321A4 (en) 2016-10-14 2020-05-13 Ultragenyx Pharmaceutical Inc. USE OF TONIFYING AGENTS TO IMPROVE THE YIELD OF RECOMBINANT ADENO-ASSOCIATED VIRUS
WO2018175775A1 (en) 2017-03-22 2018-09-27 Dimension Therapeutics Cell culture methods involving hdac inhibitors or rep proteins
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CN110835622B (zh) * 2018-08-16 2021-04-27 上海药明生物技术有限公司 用于调节哺乳动物细胞乳酸代谢的培养基及其应用
EP4121520A1 (en) 2020-03-16 2023-01-25 Ultragenyx Pharmaceutical Inc. Methods for enhancing recombinant adeno-associated virus yield
CN118871575A (zh) * 2022-02-21 2024-10-29 学校法人日本医科大学 病毒载体生产增强剂及产生病毒载体的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
AU8200191A (en) 1990-07-09 1992-02-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
RU2012335C1 (ru) 1991-07-04 1994-05-15 Уфимский научно-исследовательский институт глазных болезней Ингибитор вируса простого герпеса
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
CA2141574C (en) 1992-07-31 2009-11-24 David Knipe Herpesvirus vaccines
US7223411B1 (en) 1992-07-31 2007-05-29 Dana-Farber Cancer Institute Herpesvirus replication defective mutants
US6833271B2 (en) 1996-12-04 2004-12-21 Medi-Cult A/S Serum-free cell culture media
GB9816856D0 (en) 1998-08-03 1998-09-30 Univ London Cell lines for virus growth
US6783972B1 (en) * 1998-09-22 2004-08-31 University Of Florida Research Foundation Methods for large-scale production of recombinant AAV vectors
US6593123B1 (en) 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
US7091029B2 (en) 2002-09-23 2006-08-15 Applied Genetics Technologies Corporation High titer recombinant AAV production
US7427396B2 (en) 2004-06-03 2008-09-23 Genzyme Corporation AAV vectors for gene delivery to the lung
CN100348718C (zh) * 2005-10-18 2007-11-14 中国人民解放军军事医学科学院生物工程研究所 一种支持hek293细胞贴附培养的无动物来源成分无血清培养基
US8334295B2 (en) * 2007-06-29 2012-12-18 Korea Research Institute Of Chemical Technology Pyrimidine derivatives as HIV reverse transcriptase inhibitors

Also Published As

Publication number Publication date
JP6837094B2 (ja) 2021-03-03
RU2018144779A3 (ja) 2022-03-02
EP2943567A1 (en) 2015-11-18
BR112015016328A2 (ja) 2017-09-05
HK1249544A1 (zh) 2018-11-02
IL239824A0 (en) 2015-08-31
MX2015008861A (es) 2016-04-13
BR112015016328B1 (pt) 2023-04-18
IL239824B (en) 2019-03-31
US11299715B2 (en) 2022-04-12
RU2018144779A (ru) 2019-01-29
US20150353899A1 (en) 2015-12-10
KR20150103275A (ko) 2015-09-09
ES2651763T3 (es) 2018-01-29
HK1214840A1 (zh) 2016-08-05
NO3050055T3 (ja) 2018-02-10
JP2019187420A (ja) 2019-10-31
KR102307279B1 (ko) 2021-09-29
EP2943567B1 (en) 2017-09-13
US20220340883A1 (en) 2022-10-27
WO2014110053A1 (en) 2014-07-17
DK2943567T3 (en) 2018-01-02
RU2015133205A (ru) 2017-02-14
RU2676733C2 (ru) 2019-01-10
CN105008523A (zh) 2015-10-28
JP6534933B2 (ja) 2019-06-26
TWI608102B (zh) 2017-12-11
SG11201505333PA (en) 2015-08-28
SG10201913130PA (en) 2020-03-30
AU2014205604B2 (en) 2020-01-02
TW201446965A (zh) 2014-12-16
EP3266866B1 (en) 2019-03-06
CA2897444A1 (en) 2014-07-17
AR094389A1 (es) 2015-07-29
CN105008523B (zh) 2020-03-27
JP2016504913A (ja) 2016-02-18
MX360470B (es) 2018-11-05
AU2014205604A1 (en) 2015-08-13
BR122020002822B1 (pt) 2023-04-18
HUE037482T2 (hu) 2018-08-28
EP3521420A1 (en) 2019-08-07
EP3266866A1 (en) 2018-01-10

Similar Documents

Publication Publication Date Title
SG10201806715TA (en) Use of inos inhibitors to increase viral yield in culture
MX2020003096A (es) Formulaciones farmaceuticas de un inhibidor de hidroxilasa de hif.
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
MY181688A (en) Improved production of fatty acid derivatives
EP2808318A4 (en) CRYSTALLINE FORM OF PROSTAGLANDIN ANALOGUE, PROCESS FOR PREPARING SAME AND USE THEREOF
EP2803657A4 (en) CRYSTAL FORM OF PROSTAGLANDINANALOGA AND METHOD OF PREPARING THEREOF AND USE THEREOF
MX371093B (es) Compuestos de microarn y metodos para modular al mir-122.
PH12016500500A1 (en) A viral vaccine and methods of manufacture thereof
MX365302B (es) Métodos de monitoreo terapéutico del gliceril tri- [ 4-fenilbutirato] (hpn-100) para usarse en el tratamiento de trastornos de retención de nitrógeno.
IN2014DN07958A (ja)
MX2015012580A (es) El uso de sdf-1 para atenuar la formacion de cicatrices.
MD20130073A2 (en) New crystal form VII of agomelatine, preparation method and use thereof, and pharmaceutical composition containing the same
IN2013MU01431A (ja)
AU2016204276A1 (en) Methods for producing virus particles with simplified glycosylation of surface proteins
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.
EP3242932A4 (en) Employing human adipose-derived stem cells to propagate serum-derived hepatitis c virus and use thereof
MX2020002286A (es) Composicion para el tratamiento del cancer asociado con la infeccion del hpv.
MX2015010763A (es) Proteinas h5 del virus de la gripe h5n1 para uso como un medicamento.
WO2014115087A3 (en) A method for the preparation of recombinant human prothrombin and fibrinogen
WO2015066488A3 (en) Method for producing induced pluripotent stem cells
IN2014DN10683A (ja)
MX353587B (es) Formulaciones farmacéuticas que contienen ipidacrina y su uso para el tratamiento de trastornos de potencia y trastornos de otras formas de actividad sexual.
IN2013CH04330A (ja)
IN2013MU03086A (ja)
UA77066U (ru) Способ изготовления анатомических препаратов